Carl Zeiss Meditec’s re-rating journey should continue further
21/02/24 -"Despite our near-term estimates being slightly moderated due to the destocking of consumables and anticipated impact from volume-based procurement headwinds, our target price resets higher by c.4%, ..."
Pages
67
Language
English
Published on
21/02/24
You may also be interested by these reports :
26/07/24
No major surprises in H1 FY24 – sales and adjusted EBIT were in-line with consensus, but net income was ~2% lower. At CER, Q2 revenue grew 5.2%yoy, ...
26/07/24
Dräger reported Q2 24 figures bang in line with its preliminary figures. Revenue was up 2%, as the strength in safety was accompanied by some ...
25/07/24
Sartorius Stedim reported a decent set of Q2 figures, meeting estimates. However, the stock has lost over 7% since the announcement, as investors ...
25/07/24
Sartorius reported a decent set of Q2 figures, beating estimates. However, the stock has lost over 8% since the announcement, as investors were ...